Whole-Genome Sequence Analysis of CTX-M Containing *Escherichia coli* Isolates from Retail Meats and Cattle in the United States

Daniel A. Tadesse,¹ Cong Li,¹ Sampa Mukherjee,¹ Chih-Hao Hsu,¹ Sonya Bodeis Jones,¹ Stuart A. Gaines,¹ Claudine Kabera,¹ Guy H. Loneragan,² Mary Torrence,³ Dayna M. Harhay,⁴ Patrick F. McDermott,¹ and Shaohua Zhao¹

In recent years, there have been increased reports on the detection of extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli* and *Salmonella* strains from food-producing animals and animal products in the United States. We characterized 18 ESBL *E. coli* isolates from cattle ($n=5$), chicken breast ($n=5$), ground turkey ($n=6$), ground beef ($n=1$), and pork chops ($n=1$) that were collected by the National Antimicrobial Resistance Monitoring System (NARMS) between 2011 and 2015. *In vitro* antimicrobial susceptibility testing was done against a panel of 14 antimicrobials followed by a secondary panel of 9 β -lactam agents. Whole-genome sequencing was used to characterize the resistome, plasmids, and the genetic structures of the ESBL genes. All ESBL-producing *E. coli* isolates were resistant to at least three antimicrobial classes and carried various *bla*_{CTX-M} genes. Most of the cattle and ground turkey isolates carried *bla*_{CTX-M-27}. In chicken breast isolates, *bla*_{CTX-M-1} was present as part of an *ISEcp1* transposition unit carried on a plasmid that shares sequence similarity with the backbone structure of the IncI plasmid. Isolates carrying the *bla*_{CTX-M-14} and *bla*_{CTX-M-15} genes, widely distributed in human clinical isolates, were also isolated. To our knowledge, this is the first report of the widely distributed *bla*_{CTX-M-14} and *bla*_{CTX-M-15} in *E. coli* isolates from retail meat samples in the United States. Different insertional sequences were identified upstream of these *bla*_{CTX-Ms}, including *ISEcp1*, IS26, and IS903-*D*. CTX-M in *E. coli* from food animals and retail chicken breast were often present on plasmids with other resistance genes. Other resistance genes identified included *aadA*, *strA*, *strB*, *aac(3)-IIa*, *aac(3)-VIa*, *aph(3')-Ic*, *bla*_{TEM}, *bla*_{HERA-3}, *floR*, *sul1*, *sul2*, *catA1*, *tetA*, *tetB*, *dfrA*, and *qacE*. These data describe the emergence of CTX-M-carrying *E. coli* isolates in food animals and animal products monitored by NARMS program.

Keywords: *Escherichia coli*, ESBL, CTX-M

Introduction

EXTENDED-SPECTRUM BETA-LACTAMASES (ESBLs) are the most common cephalosporin resistance mechanism reported in members of the Enterobacteriaceae family.¹ ESBLs are a group of enzymes with the ability to hydrolyze oxyimino-cephalosporins and thus cause resistance to cefotaxime, ceftazidime, ceftriaxone, cefuroxime, and cefepime, as well as monobactams (e.g., aztreonam).² The introduction of extended-spectrum cephalosporins in clinical practice in the 1970s was soon followed by reports of

resistant strains of Enterobacteriaceae producing ESBLs.³ Since then, the occurrence of infection due to ESBL-resistant Enterobacteriaceae has rapidly increased and has become a major problem worldwide. In the United States, the Centers for Disease Control and Prevention estimates 26,000 infections and 1,700 deaths annually due to ESBL-producing Enterobacteriaceae.⁴

CTX-M-producing *Escherichia coli* have been associated with both hospital-acquired and community infections, mostly in urinary tract infections and bacteremia.^{5–8} Studies over the last decade have shown that CTX-M-type ESBLs

¹Division of Animal and Food Microbiology, U.S. FDA, CVM, Laurel, Maryland.

²Texas Tech University, Department of Animal and Food Science, Lubbock, Texas.

³U.S. FDA–CFRAN, Office of Applied Research and Safety Assessment (OARSA), Laurel, Maryland.

⁴USDA–ARS, U.S. Meat Animal Research Center, Meat Safety and Quality Research Unit, Clay Center, Nebraska.

have become the predominant enzyme type in many parts of the world,⁹ and have spread rapidly through clinical populations of Enterobacteriaceae.¹⁰ Reports from several countries describe the presence of CTX-M-producing *E. coli* strains in apparently healthy food animals^{11–13} and food animal products,¹² as well as pets¹⁴ and wild birds.¹⁵ Although CTX-M-producing strains appear to have quickly spread worldwide, the increased prevalence of *E. coli* carrying these β -lactamases in numerous U.S. hospitals became apparent in the early 2000s.^{7,10,16}

Intestinal carriage of CTX-M-producing bacteria in food-producing animals and contamination of retail meat might contribute to increased occurrences of infections with ESBL-producing bacteria in humans. A study on the presence of indistinguishable *E. coli* genotypes carrying CTX-M genes obtained from poultry, poultry products, and human clinical samples in the Netherlands has suggested the possible exchange of these genes through the food chain.¹² In the United States, few CTX-M ESBLs have been reported from food animals and animal products.^{11,17–19} The National Antimicrobial Resistance Monitoring System (NARMS) monitors changes in antimicrobial susceptibilities of zoonotic foodborne bacteria to medically important antimicrobials, including β -lactam antibiotics. Whole-genome sequencing has improved our ability to monitor resistomes and helps to identify and characterize emerging resistance genes and mobile genetic elements that facilitate the spread of these genes. The aim of this study was to investigate and characterize antimicrobial resistance genes and mobile genetic elements associated with phenotypically positive ESBL *E. coli* isolates recovered from cattle and retail meat samples collected through the NARMS program between 2011 and 2015. This information will help to characterize the molecular epidemiology of CTX-M carrying *E. coli* isolates in food animals and animal products monitored by the NARMS program.

Materials and Methods

Bacterial strains

Eighteen phenotypically positive ESBL *E. coli* isolates recovered from cattle fecal samples ($n=5$) and retail meats (chicken breast [$n=5$], ground turkey [$n=6$], ground beef [$n=1$], and pork chops [$n=1$]) by the NARMS program between 2011 and 2015 were identified and selected for characterization. The isolates were identified from a total of 8,721 *E. coli* isolates recovered from fecal samples of healthy cattle and retail meat samples. The fecal isolates ($n=3,079$) were recovered from healthy cattle as part of a NARMS on-farm pilot program to monitor antimicrobial resistance in foodborne pathogens. The retail meat *E. coli* isolates ($n=5,642$) were recovered from chicken breast, chicken wing, pork chops, ground beef, and ground turkey.

In vitro antimicrobial susceptibility testing

The bacterial isolates were tested for antimicrobial drug susceptibility using the Sensititre™ semiautomated antimicrobial susceptibility system (ThermoFisher Scientific, Trek Diagnostics, Cleveland, OH) following the manufacturer's instructions. The antimicrobials tested were as follows: amoxicillin/clavulanic acid (AUG), ampicillin (AMP), azithromycin (AZM), cefoxitin (FOX), ceftiofur (TIO), ceftriaxone (CRO),

chloramphenicol (CHL), ciprofloxacin (CIP), gentamicin (GEN), nalidixic acid (NAL), streptomycin (STR), sulfamethoxazole (SMX), tetracycline (TET), and trimethoprim/sulfamethoxazole (SXT).

A total 321 *E. coli* isolates with minimum inhibitory concentrations (MICs) $\geq 8 \mu\text{g/mL}$ for ceftiofur and/or $\geq 4 \mu\text{g/mL}$ for ceftriaxone for isolates recovered before 2015 and $\geq 2 \mu\text{g/mL}$ for isolates recovered in 2015 were selected for further testing with a second panel of 9 β -lactam antimicrobials: aztreonam (ATM), cequinome (CQN), imipenem (IMI), cefepime (FEP), piperacillin–tazobactam (TZP), ceftazidime (TAZ), ceftazidime–clavulanic acid (CAZ/CLA), cefotaxime (FOT), and cefotaxime–clavulanic acid (CTX/CLA). The Clinical and Laboratory Standards Institute (CLSI) confirmatory test for ESBL production was used and is based on cefotaxime and ceftazidime MICs with and without clavulanic acid. Isolates showing a three or more twofold concentration decrease in the cefotaxime and ceftazidime MICs when tested in combination with clavulanate versus the MICs of cefotaxime and ceftazidime when tested alone are considered ESBL⁺.²⁰

E. coli ATCC 25922, *Enterococcus faecalis* ATCC 29212, *Staphylococcus aureus* ATCC 29213, *Pseudomonas aeruginosa* ATCC 27853, and *Klebsiella pneumoniae* ATCC 700603 were used as quality control organisms for MIC determinations. Results were interpreted according to CLSI guidelines for broth microdilution methods with the exception of STR (NARMS resistance breakpoint, $\geq 32 \mu\text{g/mL}$), AZM (NARMS resistance breakpoint, $\geq 32 \mu\text{g/mL}$), and CQN (NARMS resistance breakpoint, $\geq 32 \mu\text{g/mL}$).²⁰

Conjugation

Conjugation experiments using a plate mating protocol were used to determine the transferability of resistance phenotypes and localize CTX-M genes to conjugative plasmids. We selected seven *E. coli* isolates that carried different CTX-M genes [N36254PS (*bla*_{CTX-M-32}), N36410PS (*bla*_{CTX-M-27}), N37058PS (*bla*_{CTX-M-32}), N40513 (*bla*_{CTX-M-1}), N40607 (*bla*_{CTX-M-1}), N46045 (*bla*_{CTX-M-15}), and N51980 (*bla*_{CTX-M-14})] as donor cells. MAX Efficiency[®] DH5 α ™ *E. coli* Competent Cells (Invitrogen, Carlsbad, CA) were used as recipients. The donors and recipients were grown in 2 mL LB medium (Becton Dickinson, Sparks, MD) at 37°C in a shaker incubator for 16–18 hours. Ten microliters of donor cells were spotted on top of 10 μL of recipient strain (DH5 α) on blood agar plates and incubated at 37°C overnight. Each co-culture was then scraped from the plate and resuspended in 1 mL LB broth. Ceftiofur and nalidixic acid (Sigma-Aldrich, St. Louis, MO) were used as selective agents for the donor and recipient strains, respectively. Transconjugants were selected on LB agar containing nalidixic acid (30 $\mu\text{g/mL}$) and ceftiofur (4 $\mu\text{g/mL}$). The MICs of donors, recipients, and transconjugants were determined using the Sensititre semiautomated antimicrobial susceptibility system. The β -lactam susceptibility testing panel was used to confirm the phenotype.

Five transconjugants from each experiment were tested for the presence of CTX-M genes using PCR primers designed for CTX-M-1 group (forward primer, 5'-ATGGTTA AAAAATCACTGCGTCAGT-3'; reverse primer, 5'-TTAC AAACCGTTGGTGAGATTTTAGCC-3') and CTX-M-9 group (forward primer, 5'-ATGGTGACAAAGAGAGTGCC

AACGG-3'; reverse primer, 5'-TTACAGCCCTTCGGCGA TGATTCT-3'). The expected amplicon fragment size for CTX-M group 1 and 9 was 876 and 846 bp, respectively. The PCR amplification conditions included initial denaturation at 95°C for 10 minutes, 30 cycles of denaturing at 94°C for 30 seconds, annealing at 58°C for 60 seconds, and extension at 72°C for 60 seconds, and followed by final extension at 72°C for 7 minutes.

PCR-based plasmid replicon typing of transconjugants

Genomic DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen, Valencia, CA) following the manufacturer's instructions. Amplification of plasmid replicon targets was carried out following the protocol described by Johnson *et al.*²¹ with minor modifications for IncP characterization. For IncP, a simplex PCR with an annealing temperature of 65°C was used. The amplified products were separated by gel electrophoresis on 1.0% agarose gels.

Whole-genome sequencing

Whole-genome sequencing was used to characterize the resistome and plasmids in all strains ($n=18$). Briefly, DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen) following the manufacturer's instructions. Whole-genome sequencing was performed on the MiSeq Desktop Sequencer using v2 sequencing reagent kits (Illumina, San Diego, CA). A *de novo* assembly was performed using CLC Genomics Workbench version 8.0 (Qiagen). Contigs of less than 200 bp were removed from analysis. The number of assembled contigs ranged between 78 and 258 with an average coverage of $50\times$.

Resistome analysis

Resistance genes were identified using BLASTX^a and the ResFinder resistance gene database.²² The BLASTX results were processed with in-house PERL scripts to identify antimicrobial resistance genes using an 85% amino acid identity and 50% minimum sequence length.

Phylogenetic analysis

The Center for Food Safety and Applied Nutrition (CFSAN) SNP pipeline^b was used to create the single nucleotide polymorphism (SNP) matrices from sequence data for the phylogenetic analysis. SNP redundancy by linkage disequilibrium was reduced and the phylogenetic tree was constructed with the maximum likelihood algorithm using the SNPhylo package.²³

Plasmid profiling

Identification of the plasmid type was done using the PlasmidFinder database.^c The cutoff threshold for identity was set at 95% to determine the existence for a particular plasmid.

Multilocus sequence typing profiling

E. coli multilocus sequence typing (MLST) allelic profiles and sequences were downloaded from the PubMLST database.^d A total of 7,113 profiles for 7 different loci were used for the MLST. The SRST2 pipeline²⁴ was used to determine the MLST type for our *E. coli* isolates.

Nucleotide sequence accession numbers

The whole-genome sequence data reported in this study have been deposited at DDBJ/ENA/GenBank under the following accession numbers: AZCE000000000, AZCG000000000, AZCB000000000, AZCC000000000, AZCD000000000, AZCF000000000, AZCH000000000, NTMS000000000, NTMT000000000, NTMU000000000, NTMV000000000, NTMW000000000, NTMX000000000, NTMY000000000, NTMZ000000000, NTNA000000000, NTNBN000000000, and NTNC000000000.

Results

In vitro antimicrobial susceptibility testing of *E. coli* isolates

The antimicrobial resistance profiles of phenotypically positive ESBL *E. coli* isolates are shown in Table 1. All the isolates were resistant to ampicillin, ceftiofur, ceftriaxone, and cefotaxime, as expected. Three of the 5 cattle and 2 of the 13 retail meat *E. coli* isolates were resistant to ceftazidime, a fourth-generation cephalosporin. In addition, one of the cattle *E. coli* isolates and two of retail meat isolates showed resistance to aztreonam, a monobactam. Among the 18 strains producing ESBL, all had a three or more twofold concentration decrease in MIC for cefotaxime and ceftazidime in combination with clavulanic acid than the MIC when tested alone (Table 2). Other non- β -lactam resistances observed were to sulfisoxazole (15/18), tetracycline (14/18), chloramphenicol (3/18) streptomycin (9/18), nalidixic acid (1/18), and trimethoprim/sulfamethoxazole (4/18).

Conjugation and plasmid typing

At least two plasmid types were detected using PlasmidFinder from each of the *bla*_{CTX-M}⁺ *E. coli* isolates (Fig. 1). The conjugation results showed that *bla*_{CTX-M} genes can be transferred by broth mating. The transfer of *bla*_{CTX-M} gene was confirmed by PCR. We further confirmed the plasmid replicon type of the transconjugant with the ESBL phenotype using PCR-based replicon typing. Based on the replicon typing, the two conjugative plasmid types that carried the CTX-M genes were IncI1 and IncF, present in isolates from chicken breast and cattle feces, respectively. One of the *bla*_{CTX-M} genes identified from cattle isolates (*bla*_{CTX-M-32}) was not transferable by conjugation. Other resistance phenotypes co-transferred by conjugation include Tet^R and Smx^R (Table 1).

Resistome analysis in ESBL *E. coli* isolates

Characterization of resistance genes was conducted using whole-genome sequencing. The distribution of resistance genes is shown in Fig. 2. The ESBL genotypes in our

^a<https://blast.ncbi.nlm.nih.gov/>

^b<http://snp-pipeline.readthedocs.io/>

^c<https://cge.cbs.dtu.dk/services/PlasmidFinder>

^d<https://pubmlst.org/>

TABLE 1. MINIMUM INHIBITORY CONCENTRATION VALUES OF EXTENDED-SPECTRUM BETA-LACTAMASE-POSITIVE *ESCHERICHIA COLI* ISOLATES OBTAINED FROM FECAL SAMPLES OF HEALTHY CATTLE AND RETAIL MEAT SAMPLES

ID	Source	Antimicrobials ^a													
		AMC ≥32/16	AMP ≥32	AZM ^b ≥32	FOX ≥32	CRO ≥4	MEM ≥4	CHL ≥32	CIP ≥4	NAL ≥32	GEN ≥16	STR ^b ≥32	TET ≥16	FIS ≥16	SXT ≥4/76
N36254PS	Farm, fecal	4	>32	4	8	8	≤0.06	8	≤0.015	2	0.5	32	>32	>256	≤0.12
N36410PS	Farm, fecal	8	>32	4	8	>64	≤0.06	8	≤0.015	2	0.5	16	≤4	>256	>4
N37058PS	Farm, fecal	4	>32	4	4	32	≤0.06	>32	1	4	0.5	32	>32	>256	0.25
N37122PS	Farm, fecal	4	>32	4	8	>64	≤0.06	8	≤0.015	2	1	8	≤4	>256	>4
N37139PS	Farm, fecal	4	>32	4	8	64	≤0.06	8	≤0.015	2	0.5	8	≤4	>256	>4
N40513	Chicken breast	8	>32	4	4	64	≤0.06	4	≤0.015	2	0.5	8	>32	>256	0.5
N40607	Chicken breast	8	>32	2	8	>64	≤0.06	4	≤0.015	4	0.5	16	>32	>256	0.5
N43684	Chicken breast	4	>32	4	4	>64	≤0.06	4	≤0.015	2	0.5	8	≤4	>256	1
N44807	Ground turkey	8	>32	4	8	>64	≤0.06	8	≤0.015	4	≤0.25	>64	>32	≤16	≤0.12
N46045	Ground beef	32	>32	4	8	>64	≤0.06	>32	≤0.015	4	0.5	>64	>32	>256	>4
N51980	Pork chop	8	>32	4	4	64	≤0.06	8	≤0.015	2	0.5	>64	>32	≤16	≤0.12
N53976	Ground turkey	4	>32	2	4	32	0.25	4	0.5	2	4	8	>32	>256	2
N56041	Ground turkey	16	>32	2	4	>64	≤0.06	>32	0.12	>32	0.5	>64	32	>256	≤0.12
N56738	Ground turkey	8	>32	4	4	>64	≤0.06	8	≤0.015	2	1	64	>32	>256	≤0.12
N58201	Chicken breast	8	>32	4	4	64	≤0.06	4	≤0.015	4	4	8	>32	>256	0.5
N60559	Chicken breast	8	>32	4	8	64	≤0.06	4	≤0.015	2	>16	4	>32	>256	1
N60592	Ground turkey	8	>32	4	4	64	≤0.06	4	≤0.015	2	16	64	>32	>256	≤0.12
N63148	Ground turkey	4	>32	4	2	64	≤0.06	8	≤0.015	2	0.5	8	32	≤16	≤0.12

^aCLSI breakpoint.^bNARMS breakpoint.

AMC, amoxicillin/clavulanic acid; AMP, ampicillin; AZM, azithromycin; CHL, chloramphenicol; CIP, ciprofloxacin; CRO, ceftriaxone; FIS, sulfisoxazole; FOX, cefoxitin; GEN, gentamicin; MEM, meropenem; NAL, nalidixic acid; STR, streptomycin; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline.

TABLE 2. MINIMUM INHIBITORY CONCENTRATION VALUES FROM THE EXTENDED-SPECTRUM BETA-LACTAMASE PANEL FOR *ESCHERICHIA COLI* ISOLATES OBTAINED FROM FECAL SAMPLES OF HEALTHY CATTLE AND RETAIL MEAT SAMPLES WITH DIMINISHED SUSCEPTIBILITY OR RESISTANCE TO BROAD-SPECTRUM CEPHALOSPORINS

		Antimicrobials ^a								
		ATM ≥16	FEP ≥16	CTX ≥4	CQN ^b ≥32	CAZ ≥16	IPM ≥4	TZP ≥128/4	CTX/CLA —	CAZ/CLA —
N36254PS	Farm, fecal	2	1	8	4	1	0.12	≤0.5	≤0.06	≤0.06
N36410PS	Farm, fecal	16	4	64	>32	4	0.12	8	0.25	0.12
N37058PS	Farm, fecal	8	4	32	16	4	0.25	1	≤0.06	0.12
N37122PS	Farm, fecal	8	8	128	32	2	0.12	1	≤0.06	0.12
N37139PS	Farm, fecal	8	4	64	32	8	0.12	≤0.5	≤0.06	≤0.06
N40513	Chicken breast	8	4	16	8	1	0.25	1	≤0.06	0.25
N40607	Chicken breast	16	8	64	16	8	0.25	2	≤0.06	0.25
N43684	Chicken breast	>32	16	128	>32	8	0.25	2	0.12	0.25
N44807	Ground turkey	8	4	64	16	1	0.25	2	0.12	0.25
N46045	Ground beef	4	8	32	32	1	0.12	1	≤0.06	0.25
N51980	Pork chop	4	2	32	8	4	0.12	2	≤0.06	0.12
N53976	Ground turkey	8	8	32	16	1	0.25	2	≤0.06	0.12
N56041	Ground turkey	4	4	16	16	2	0.25	2	≤0.06	0.25
N56738	Ground turkey	4	4	32	16	4	0.12	2	≤0.06	0.12
N58201	Chicken breast	4	2	16	8	2	0.12	2	≤0.06	≤0.06
N60559	Chicken breast	4	4	16	8	1	0.25	1	≤0.06	0.25
N60592	Ground turkey	8	8	32	16	2	0.12	1	≤0.06	0.25
N63148	Ground turkey	8	2	16	8	8	0.12	4	8	8

^aCLSI breakpoint.^bNARMS breakpoint.

ATM, aztreonam; CAZ, ceftazidime; CAZ/CLA, ceftazidime-clavulanic acid; CQN, cefquinome; CTX, cefotaxime; CTX/CLA, cefotaxime-clavulanic acid; FEP, cefepime; IPM, imipenem; TZP, piperacillin-tazobactam.

FIG. 1. Plasmid and MLST profiling of *bla*_{CTX-M}-encoding *Escherichia coli* isolates. Phylogenetic tree generated based on the SNP analysis of the WGS data. The black color indicates the presence of the plasmid type based on plasmid finder.^c 6707*—a single SNP on *recA* (T176G) and 2325*—a single SNP on *purA* (G102A). MLST, multilocus sequence typing; SNP, single nucleotide polymorphism.

isolates were *bla*_{CTX-M-1}, *bla*_{CTX-M-14}, *bla*_{CTX-M-15}, *bla*_{CTX-M-27}, and *bla*_{CTX-M-32}. CTX-M β-lactamases exhibit increased hydrolytic activity against cefotaxime and ceftazidime, but generally not against ceftazidime, which has important implications for laboratory detection. Similarly, in this study, all CTX-M-positive isolates were resistant to cefotaxime and none were resistant to ceftazidime. This is the first report of *bla*_{CTX-M-14}- and *bla*_{CTX-M-15}-containing *E.*

coli isolates from NARMS retail meat program in the United States.

The CTX-M genes identified in our isolates had 100% nucleotide sequence identity with previously reported CTX-M genes. All five of the chicken breast *E. coli* isolates carried *bla*_{CTX-M-1}, four of the five cattle isolates (N36410PS, N37058PS, N37122PS, and N37139PS) had *bla*_{CTX-M-27}, and one cattle isolate (N36254PS) contained *bla*_{CTX-M-32}.

FIG. 2. Phylogenetic analysis and summary of MLST profiling and antimicrobial resistance genes identified in phenotypically positive ESBL *E. coli* isolates recovered from cattle and chicken breast. Clustering based on the SNP analysis of WGS data. The black color indicates the resistance gene identified. ESBL, extended-spectrum beta-lactamase.

^c<https://cge.cbs.dtu.dk/services/PlasmidFinder>

FIG. 3. Genetic context of insertion sequence elements (ISEp1, IS903D, and IS26) found in association with *bla_{CTX-M}* genes. CTX-M genes are indicated with *red arrows*. Insertion sequences and transposons are represented with *blue arrows*.

Three of the four *bla*_{CTX-M-27}⁺ cattle *E. coli* isolates clustered together and had identical MLST type (ST1508) (Fig. 2).

E. coli isolates recovered from ground turkey carried diverse CTX-M genes, including *bla*_{CTX-M-1} (*n* = 1), *bla*_{CTX-M-15} (*n* = 1), and *bla*_{CTX-M-27} (*n* = 4). A single *E. coli* isolate each from pork chops and ground beef carried *bla*_{CTX-M-14} and *bla*_{CTX-M-15}, respectively. The primary mechanisms responsible for the acquisition and mobilization of CTX-M genes are insertion sequences, transposons, and ISCR1. In our isolates, we identified *ISEcp1*, IS26, and IS903-*D* mobilization elements (Fig. 3). In chicken breast isolates, *bla*_{CTX-M-1} gene was present as part of an *ISEcp1* transposition unit and shares sequence similarity with the backbone structure of the IncI plasmid. Conjugation results demonstrated that *tet* and *sul* resistance genes were carried on the same IncI plasmids harboring *bla*_{CTX-M-1} gene.

Streptomycin-resistant isolates (MIC ≥ 32) carried one or more aminoglycoside resistance genes. The aminoglycoside resistance genes commonly identified in these isolates were *strA* [*aph*(3')-Ib], *strB* [*aph*(6')-Id], and *aadA1*. One isolate with a gentamicin MIC > 16 µg/mL possessed an *aac*(3)-*Ild* gene. Three *E. coli* isolates (N36410PS, N37122PS, and N37139PS) contained a class 1 integron carrying *aadA1*, *dfrA*, and *qacE* genes.

Two chloramphenicol-resistant isolates carried the *floR* gene and one contained *catA1*. All, but three *E. coli* isolates were resistant to sulfisoxazole and had either *sul1* or *sul2*. Four also carried the dihydrofolate reductase gene *dfrA*.

Discussion

CTX-M-producing strains appear to have quickly spread worldwide, with the notable exception of the United States where TEM- and SHV-type ESBL have appeared to predominate until recently. CTX-M ESBLs have been reported in the United States mainly from human clinical isolates of Enterobacteriaceae encoding for CTX-M group 1 and 9.^{7,10,16, 25,26}

Infections caused by bacteria producing CTX-M enzymes are not limited to the hospital setting.²⁷ Intestinal carriage of CTX-M-producing bacteria in food-producing animals and contamination of retail meat may contribute to increased incidences of infections with ESBL-producing bacteria in humans. Various reports have documented dissemination of ESBL-producing *E. coli* in healthy food-producing animals and animal products in several countries,^{12,13,17,28,29} and the potential of wild birds as possible reservoirs and vehicles for dissemination of CTX-Ms in the United States.¹⁵

In this study, we are reporting the first *bla*_{CTX-M-14} and *bla*_{CTX-M-15} gene carrying *E. coli* isolate from NARMS retail meat program. All *E. coli* isolates obtained before 2011 from NARMS were phenotypically and genotypically negative for *bla*_{CTX-M}.³⁰ However, McDermott *et al.* recently identified the first *bla*_{CTX-M-1}-positive *Salmonella* isolate recovered from NARMS retail meat samples in the United States.¹⁸ *Salmonella enterica* serovar Infantis isolates containing *bla*_{CTX-M-65} obtained from chicken, cattle, and human sources collected between 2012 and 2015 in the United States through routine NARMS surveillance have been reported.¹⁹ Davis *et al.*, reported *bla*_{CTX-M}-carrying *E. coli* strains among isolates collected from Washington State cattle in 2011, while none from those collected in 2008.¹³ Investigations of nontyphoidal *Salmonella* isolates of human

origin submitted to Center for Disease Control and Prevention (CDC) as part of the NARMS program between 2005 and 2007 identified *Salmonella* isolates producing CTX-M enzymes (*bla*_{CTX-M-15}, *bla*_{CTX-M-5}, and *bla*_{CTX-M-55/57}).^{31,32}

The successful spread of CTX-M genes depends on the clonal nature of strains carrying the resistance genes, and mobile genetic elements responsible for its capture and spread. *E. coli* ST131 and ST405 are by far the most important sequence types (STs) associated with the sudden worldwide increase of CTX-M genes, including *bla*_{CTX-M-15}³³ and other CTX-M genes such as *bla*_{CTX-M-1}, *bla*_{CTX-M-3}, *bla*_{CTX-M-10}, and *bla*_{CTX-M-14}.²⁶ None of our *bla*_{CTX-M}⁺ *E. coli* belonged to ST131 or ST405, indicating that the spread of CTX-M genes is not associated with the established clonal strains. We observed diverse STs carrying the same *bla*_{CTX-M} gene, and in some instances, different *bla*_{CTX-M} genes carried by the same ST. For example, *E. coli* isolates recovered from two ground turkey isolates carrying *bla*_{CTX-M-27} and two chicken breast isolates carrying *bla*_{CTX-M-1} were ST117, indicating the potential of the same ST to spread multiple CTX-M genes.

The most commonly reported mobilization elements mediating the spread of CTX-M genes include *ISEcp1*, *ISCR1*, and IS26^{34–36} and phage-related sequences.³⁷ In our isolates, different IS elements, including *ISEcp1*, IS26, and IS903-*D* were identified upstream of *bla*_{CTX-M-1}, *bla*_{CTX-M-27}, and *bla*_{CTX-M-32} genes as previously reported elsewhere.^{38–40} All phenotypically positive ESBL *E. coli* isolates recovered from chicken breast encoded *bla*_{CTX-M-1} as part of an *ISEcp1* transposition unit and shares sequence similarity with the backbone structure of the IncI plasmid. IncII has been shown to be one of the main plasmid lineages that contribute to the dissemination of *bla*_{CTX-M-1} genes in the food chain, including chicken retail meat, the environment, and humans.⁴¹ In the Netherlands, bacteria producing ESBL isolated from chicken meat and gut of broilers predominantly carried *bla*_{CTX-M-1} located on IncII plasmids.⁴² Similarly, Day *et al.* demonstrated a widespread distribution of IncII plasmids carrying *bla*_{CTX-M-1} gene among *E. coli* recovered from humans, animals, and food products in Germany, the Netherlands, and the United Kingdom.⁴³ Furthermore, a study in the Netherlands revealed the presence of indistinguishable genotypes, CTX-M genes and plasmids, in *E. coli* obtained from poultry, retail chicken meat, and human clinical samples, suggesting possible exchange through food chain.¹²

The *bla*_{CTX-M-27} genes identified in our cattle and ground turkey *E. coli* isolates were associated with IncF plasmids. Horizontal transfer is important in the dissemination of *bla*_{CTX-M-27} gene, as evidenced by the fact that *bla*_{CTX-M-27} genes in our isolates were transferred by conjugation, confirming the location of the gene on a conjugative plasmid. IncF plasmids encode numerous addiction systems that ensure and contribute to the maintenance of antimicrobial resistance determinants and virulence factors even in the absence of antibiotic selection pressure.⁴⁴ IncF replicon-type plasmids carrying *bla*_{CTX-M-27} have been documented in cefotaximase-producing *E. coli* clinical isolates from Dublin, Ireland.⁴⁵ Plasmids carrying *bla*_{CTX-M} genes are often self-conjugative and carry additional resistance determinants,⁴⁶ greatly facilitating widespread distribution of alleles in different environments. A recent report has documented a case of ceftriaxone treatment failure caused by *Salmonella* Typhimurium due to

the *in vivo* acquisition of a *bla*_{CTX-M-27}-encoding IncFII group transmissible plasmid.⁴⁷

The presence of *bla*_{CTX-M-15} and *bla*_{CTX-M-14} was reported in most U.S. medical centers participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) program in 2007.^{10,25} In this study, we are reporting for the first time *bla*_{CTX-M-15}- and *bla*_{CTX-M-14}-encoding *E. coli* from retail meat samples collected in 2013. CTX-M-15 and CTX-M-14, the two most frequently identified CTX-M enzyme worldwide, have been detected in bacteria isolated from humans, animals, and the environment.^{17,42,48} A recent study from six community hospitals in North Carolina and Virginia from 2010 to 2012 demonstrated that 80% of ESBL-producing isolates contained CTX-M enzymes. In these isolates, ST131 was associated with 48% of *bla*_{CTX-M-15}-producing *E. coli* isolates and 66% of the *bla*_{CTX-M-14}-producing *E. coli* isolates.⁴⁹ While the prevalence of these two successful CTX-M enzymes is low from domestic food animal sources, monitoring will continue to help determine whether this mechanism is becoming more widespread among animal and food strains of *E. coli* in the United States.

Acknowledgments

We thank NARMS participating state and local health departments, USDA-ARS, and University partners involved in sample collection. We would also like to thank Dr. Maureen Davidson for critical review of the article before submission. This work was supported by the U.S. Food and Drug Administration with internal funds as part of routine work. The views expressed in this article are those of the authors and do not necessarily reflect the official policy of the Department of Health and Human Services, the U.S. Food and Drug Administration, the U.S. Department of Agriculture, or the U.S. Government. Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the U.S. Food and Drug Administration or the USDA. The USDA is an equal opportunity provider and employer.

Disclosure Statement

G.H.L. has accepted consulting fees for service on scientific advisory boards, honoraria, and travel expenses from various manufacturers of animal pharmaceuticals.

References

- Bradford, P.A. 2001. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin. Microbiol. Rev.* 14:933–951.
- Paterson, D.L., and R.A. Bonomo. 2005. Extended-spectrum beta-lactamases: a clinical update. *Clin. Microbiol. Rev.* 18: 657–686.
- Shah, P.M., and W. Stille. 1983. *Escherichia coli* and *Klebsiella pneumoniae* strains more susceptible to cefoxitin than to third generation cephalosporins. *J. Antimicrob. Chemother.* 11:597–598.
- CDC. 2013. Antibiotic Resistance Threats in the United States, 2013. Centers for Disease Control and Prevention.

- Atlanta, GA. Available at www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
- Woodford, N., A. Carattoli, E. Karisik, A. Underwood, M.J. Ellington, and D.M. Livermore. 2009. Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major *Escherichia coli* lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. *Antimicrob. Agents Chemother.* 53:4472–4482.
- Pitout, J.D., P. Nordmann, K.B. Laupland, and L. Poirel. 2005. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. *J. Antimicrob. Chemother.* 56:52–59.
- Lewis, J.S., M. Herrera, B. Wickes, J.E. Patterson, and J.H. Jorgensen. 2007. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. *Antimicrob. Agents Chemother.* 51:4015–4021.
- Canton, R., A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, and T.M. Coque. 2008. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. *Clin. Microbiol. Infect.* 14(Suppl 1): 144–153.
- D'Andrea, M.M., F. Arena, L. Pallecchi, and G.M. Ros-solini. 2013. CTX-M-type beta-lactamases: a successful story of antibiotic resistance. *Int. J. Med. Microbiol.* 303: 305–317.
- Castanheira, M., R.E. Mendes, P.R. Rhomberg, and R.N. Jones. 2008. Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). *Microb. Drug Resist.* 14:211–216.
- Wittum, T.E., D.F. Mollenkopf, J.B. Daniels, A.E. Parkinson, J.L. Mathews, P.R. Fry, M.J. Abley, and W.A. Gebreyes. 2010. CTX-M-type extended-spectrum beta-lactamases present in *Escherichia coli* from the feces of cattle in Ohio, United States. *Foodborne Pathog. Dis.* 7:1575–1579.
- Leverstein-van Hall, M.A., C.M. Dierikx, S.J. Cohen, G.M. Voets, M.P. van den Munckhof, A. van Essen-Zandbergen, T. Platteel, A.C. Fluit, N. Sande-Bruinsma, J. Scharinga, M.J. Bonten, D.J. Mevius; National ESBL Surveillance Group. 2011. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. *Clin. Microbiol. Infect.* 17:873–880.
- Davis, M.A., W.M. Sischo, L.P. Jones, D.A. Moore, S. Ahmed, D.M. Short, and T.E. Besser. 2015. Recent emergence of *Escherichia coli* with cephalosporin resistance conferred by blaCTX-M on Washington State dairy farms. *Appl. Environ. Microbiol.* 81:4403–4410.
- Carattoli, A., S. Lovari, A. Franco, G. Cordaro, P. Di Matteo, and A. Battisti. 2005. Extended-spectrum beta-lactamases in *Escherichia coli* isolated from dogs and cats in Rome, Italy, from 2001 to 2003. *Antimicrob. Agents Chemother.* 49:833–835.
- Poirel, L., A. Potron, C. De La Cuesta, T. Cleary, P. Nordmann, and L.S. Munoz-Price. 2012. Wild coastline birds as reservoirs of broad-spectrum-beta-lactamase-producing Enterobacteriaceae in Miami Beach, Florida. *Antimicrob. Agents Chemother.* 56:2756–2758.
- Moland, E.S., J.A. Black, A. Hossain, N.D. Hanson, K.S. Thomson, and S. Pottumarthy. 2003. Discovery of CTX-M-like extended-spectrum beta-lactamases in *Escherichia coli* isolates from five US States. *Antimicrob. Agents Chemother.* 47:2382–2383.

17. Cottell, J.L., M.A. Webber, N.G. Coldham, D.L. Taylor, A.M. Cerdeno-Tarraga, H. Hauser, N.R. Thomson, M.J. Woodward, and L.J. Piddock. 2011. Complete sequence and molecular epidemiology of IncK epidemic plasmid encoding blaCTX-M-14. *Emerg. Infect. Dis.* 17:645–652.
18. McDermott, P.F., G.H. Tyson, C. Kabera, Y. Chen, C. Li, J.P. Folster, S.L. Ayers, C. Lam, H.P. Tate, and S. Zhao. 2016. Whole-genome sequencing for detecting antimicrobial resistance in nontyphoidal *Salmonella*. *Antimicrob. Agents Chemother.* 60:5515–5520.
19. Tate, H., J.P. Folster, C.H. Hsu, J. Chen, M. Hoffmann, C. Li, C. Morales, G.H. Tyson, S. Mukherjee, A.C. Brown, A. Green, W. Wilson, U. Dessai, J. Abbott, L. Joseph, J. Haro, S. Ayers, P.F. McDermott, and S. Zhao. 2017. Comparative analysis of extended-spectrum-beta-lactamase CTX-M-65-producing *Salmonella enterica* serovar Infantis isolates from humans, food animals, and retail chickens in the United States. *Antimicrob. Agents Chemother.* 61:e00488-17.
20. CLSI. 2017. Performance Standards for Antimicrobial Susceptibility Testing; 27th Informational Supplement. CLSI Document M100–S27. Clinical and Laboratory Standards Institute, Wayne, PA.
21. Johnson, T.J., Y.M. Wannemuehler, S.J. Johnson, C.M. Logue, D.G. White, C. Doetkott, and L.K. Nolan. 2007. Plasmid replicon typing of commensal and pathogenic *Escherichia coli* isolates. *Appl. Environ. Microbiol.* 73:1976–1983.
22. Zankari, E., H. Hasman, S. Cosentino, M. Vestergaard, S. Rasmussen, O. Lund, F.M. Aarestrup, and M.V. Larsen. 2012. Identification of acquired antimicrobial resistance genes. *J. Antimicrob. Chemother.* 67:2640–2644.
23. Lee, T.H., H. Guo, X. Wang, C. Kim, and A.H. Paterson. 2014. SNPhylo: a pipeline to construct a phylogenetic tree from huge SNP data. *BMC Genomics* 15:162.
24. Inouye, M., H. Dashnow, L.A. Raven, M.B. Schultz, B.J. Pope, T. Tomita, J. Zobel, and K.E. Holt. 2014. SRST2: rapid genomic surveillance for public health and hospital microbiology labs. *Genome Med.* 6:90.
25. Castanheira, M., H.S. Sader, and R.N. Jones. 2010. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. *Microb. Drug Resist.* 16:61–65.
26. Naseer, U., and A. Sundsfjord. 2011. The CTX-M conundrum: dissemination of plasmids and *Escherichia coli* clones. *Microb. Drug Resist.* 17:83–97.
27. Pitout, J.D., and K.B. Laupland. 2008. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect. Dis.* 8:159–166.
28. Horton, R.A., L.P. Randall, E.L. Snary, H. Cockrem, S. Lotz, H. Wearing, D. Duncan, A. Rabie, I. McLaren, E. Watson, R.M. La Ragione, and N.G. Coldham. 2011. Fecal carriage and shedding density of CTX-M extended-spectrum {beta}-lactamase-producing *Escherichia coli* in cattle, chickens, and pigs: implications for environmental contamination and food production. *Appl. Environ. Microbiol.* 77:3715–3719.
29. Tamang, M.D., H.M. Nam, T.S. Kim, G.C. Jang, S.C. Jung, and S.K. Lim. 2011. Emergence of extended-spectrum beta-lactamase (CTX-M-15 and CTX-M-14)-producing nontyphoid *Salmonella* with reduced susceptibility to ciprofloxacin among food animals and humans in Korea. *J. Clin. Microbiol.* 49:2671–2675.
30. Zhao, S., K. Blickenstaff, A. Glenn, S.L. Ayers, S.L. Friedman, J.W. Abbott, and P.F. McDermott. 2009. Beta-lactam resistance in *Salmonella* strains isolated from retail meats in the United States by the National Antimicrobial Resistance Monitoring System between 2002 and 2006. *Appl. Environ. Microbiol.* 75:7624–7630.
31. Sjolund-Karlsson, M., R. Howie, A. Krueger, R. Rickert, G. Pecic, K. Lupoli, J.P. Folster, and J.M. Whichard. 2011. CTX-M-producing non-Typhi *Salmonella* spp. isolated from humans, United States. *Emerg. Infect. Dis.* 17:97–99.
32. Sjolund-Karlsson, M., R. Rickert, C. Matar, G. Pecic, R.L. Howie, K. Joyce, F. Medalla, E.J. Barzilay, and J.M. Whichard. 2010. *Salmonella* isolates with decreased susceptibility to extended-spectrum cephalosporins in the United States. *Foodborne Pathog. Dis.* 7:1503–1509.
33. Peirano, G., and J.D. Pitout. 2010. Molecular epidemiology of *Escherichia coli* producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. *Int. J. Antimicrob. Agents* 35:316–321.
34. Toleman, M.A., P.M. Bennett, and T.R. Walsh. 2006. ISCR elements: novel gene-capturing systems of the 21st century? *Microbiol. Mol. Biol. Rev.* 70:296–316.
35. Cullik, A., Y. Pfeifer, R. Prager, H. von Baum, and W. Witte. 2010. A novel IS26 structure surrounds blaCTX-M genes in different plasmids from German clinical *Escherichia coli* isolates. *J. Med. Microbiol.* 59:580–587.
36. Partridge, S.R., J.A. Ellem, S.G. Tetu, Z. Zong, I.T. Paulsen, and J.R. Iredell. 2011. Complete sequence of pJIE143, a pir-type plasmid carrying ISEcp1-blaCTX-M-15 from an *Escherichia coli* ST131 isolate. *Antimicrob. Agents Chemother.* 55:5933–5935.
37. Oliver, A., T.M. Coque, D. Alonso, A. Valverde, F. Baquero, and R. Canton. 2005. CTX-M-10 linked to a phage-related element is widely disseminated among Enterobacteriaceae in a Spanish hospital. *Antimicrob. Agents Chemother.* 49:1567–1571.
38. Bou, G., M. Cartelle, M. Tomas, D. Canle, F. Molina, R. Moure, J.M. Eiros, and A. Guerrero. 2002. Identification and broad dissemination of the CTX-M-14 beta-lactamase in different *Escherichia coli* strains in the northwest area of Spain. *J. Clin. Microbiol.* 40:4030–4036.
39. Chanawong, A., F.H. M'Zali, J. Heritage, J.H. Xiong, and P.M. Hawkey. 2002. Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China. *Antimicrob. Agents Chemother.* 46:630–637.
40. Dutour, C., R. Bonnet, H. Marchandin, M. Boyer, C. Chanal, D. Sirot, and J. Sirot. 2002. CTX-M-1, CTX-M-3, and CTX-M-14 beta-lactamases from Enterobacteriaceae isolated in France. *Antimicrob. Agents Chemother.* 46:534–537.
41. Zurfluh, K., G. Jakobi, R. Stephan, H. Hachler, and M. Nuesch-Inderbinen. 2014. Replicon typing of plasmids carrying bla CTX-M-1 in Enterobacteriaceae of animal, environmental and human origin. *Front. Microbiol.* 5:555.
42. Fischer, E.A., C.M. Dierikx, A. van Essen-Zandbergen, H.J. van Roermund, D.J. Mevius, A. Stegeman, and D. Klinkenberg. 2014. The IncI1 plasmid carrying the blaCTX-M-1 gene persists in in vitro culture of a *Escherichia coli* strain from broilers. *BMC Microbiol.* 14:77.
43. Day, M.J., I. Rodriguez, A. van Essen-Zandbergen, C. Dierikx, K. Kadlec, A.K. Schink, G. Wu, M.A. Chattaway, V. DoNascimento, J. Wain, R. Helmuth, B. Guerra, S. Schwarz, J. Threlfall, M.J. Woodward, N. Coldham, D. Mevius, and N. Woodford. 2016. Diversity of STs, plasmids and ESBL genes among *Escherichia coli* from humans, animals and food in Germany, the Netherlands and the UK. *J. Antimicrob. Chemother.* 71:1178–1182.

44. Carattoli, A. 2011. Plasmids in Gram negatives: molecular typing of resistance plasmids. *Int. J. Med. Microbiol.* 301: 654–658.
45. Burke, L., H. Humphreys, and D. Fitzgerald-Hughes. 2016. The molecular epidemiology of resistance in cefotaximase-producing *Escherichia coli* clinical isolates from Dublin, Ireland. *Microb. Drug Resist.* 22:552–558.
46. Rossolini, G.M., M.M. D'Andrea, and C. Mugnaioli. 2008. The spread of CTX-M-type extended-spectrum beta-lactamases. *Clin. Microbiol. Infect.* 14(Suppl 1):33–41.
47. McCollister, B., C.V. Kotter, D.N. Frank, T. Washburn, and M.G. Jobling. 2016. Whole-genome sequencing identifies in vivo acquisition of a blaCTX-M-27-carrying IncFII transmissible plasmid as the cause of ceftriaxone treatment failure for an invasive *Salmonella enterica* serovar Typhimurium infection. *Antimicrob. Agents Chemother.* 60:7224–7235.
48. Hawkey, P.M., and A.M. Jones. 2009. The changing epidemiology of resistance. *J. Antimicrob. Chemother.* 64(Suppl 1): i3–i10.
49. Chen, L.F., J.T. Freeman, B. Nicholson, A. Keiger, S. Lancaster, M. Joyce, C.W. Woods, E. Cook, L. Adcock, S. Louis, A.L. Cromer, D.J. Sexton, and D.J. Anderson. 2014. Widespread dissemination of CTX-M-15 genotype extended-spectrum-beta-lactamase-producing Enterobacteriaceae among patients presenting to community hospitals in the southeastern United States. *Antimicrob. Agents Chemother.* 58:1200–1202.

Address correspondence to:
Daniel A. Tadesse, DVM, PhD
Division of Animal and Food Microbiology
U.S. FDA, CVM
8401 Muirkirk Road
Laurel, MD 20708

E-mail: daniel.tadesse@fda.hhs.gov